NOW AVAILABLE: 3-times-a-week Glatopa 40mg/mL
Also available: Once-daily Glatopa 20mg/mL
BE PART OF GENERATION G
Glatopa: a generic glatiramer acetate with an identity all its own.
If your doctor has prescribed a generic glatiramer acetate for your relapsing-form of MS—go Glatopa. Glatopa is the first FDA-approved generic for Copaxone® (glatiramer acetate), and it’s made in the USA. With Glatopa, you’re backed by GlatopaCare, which provides free, ongoing individualized support—no matter if you’re new to glatiramer acetate or making a switch. And it’s all provided by Sandoz, a Novartis Division, known for high-quality generics.
Glatopa Co-Pay Program Eligibility
The Glatopa Co-Pay Program provides up to $9,000 in annual Co-Pay support for Glatopa prescriptions. This program is not health insurance. This program is for insured patients only; uninsured cash-paying patients are not eligible. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Card may not be combined with any other rebate, coupon, or offer. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.
Glatopa Indication and Important Safety Information
Indication
Glatopa® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing-forms of multiple sclerosis.
Important Safety Information
Do not take Glatopa® if you are allergic to glatiramer acetate, mannitol, or any of the ingredients in Glatopa.
Some patients report a short-term reaction within minutes after injecting glatiramer acetate. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, fast heartbeat, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again.
Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense.
A permanent indentation under the skin (lipoatrophy) or, rarely, necrosis at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes.
The most common side effects in studies of glatiramer acetate injection are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of glatiramer acetate. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking Glatopa.
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for Glatopa.
Glatopa, GlatopaCare, and Glatopaject are registered trademarks of Novartis AG.
Copaxone is a registered trademark of Teva Pharmaceutical Industries Ltd.
©2018 Sandoz Inc., a Novartis Division, 100 College Road West, Princeton, NJ 08540. All Rights Reserved.
S-GLA-1339519 02/2018